New drug aimed at calming the itch of prurigo nodularis enters human testing

NCT ID NCT07620561

Not yet recruiting Symptom relief Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tests lebrikizumab (Ebglyss) in 15 adults with moderate-to-severe prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants receive injections every two weeks for 24 weeks. The main goals are to measure how much itching decreases and how many patients achieve clear or nearly clear skin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lebrikizumab (Ebglyss)
What this could lead to: If successful, this could point toward a new treatment option that reduces severe itching and clears skin nodules in people with prurigo nodularis.
What could go wrong: This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The drug may not work better than existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatitis prurigo prurigo nodularis Pruritus skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRURIGO NODULARIS (PN)

Contacts and locations

Locations

UM Dermatology at UM Professional Building

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.